Abstract
We report a case of a 54-year-old male renal transplant patient who received antifungal azole treatment in combination with the recently introduced immunosuppressant agent everolimus to prevent post-transplantation aspergillosis reactivation. Voriconazole was withdrawn after 1 month because of elevated concentrations (5 mg/L trough plasma determination) and hepatotoxicity, and substituted by several months of treatment with posaconazole (observed concentration range 1–2 mg/L). We observed pharmacokinetic drug interactions between both voriconazole and posaconazole, and everolimus cytochrome P450 3A4 metabolism, resulting in 7.5- and 3.8-fold increase, respectively, in everolimus blood trough concentrations. Combined therapeutic drug monitoring (TDM) of both everolimus and azole inhibitors allowed for safe and convenient modification of everolimus dosage, which was tapered to maintain a target range of 5–15 ng/mL during and after antifungal treatments. While significant in their effects, these drug interactions were able to be managed safely through a careful approach to management and use of individual TDM.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Singh N, Paterson DL. Aspergillus infections in transplant recipients. Clin Microbiol Rev 2005 Jan; 18(1): 44–69
Dodds Ashley ES, Lewis R, Lewis JS, et al. Pharmacology of systemic antifungal agents. Clin Infect Dis 2006; 43(1): S28–39
Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society. Clin Infect Dis 2008 Feb; 46(3): 327–60
Shakeri-Nejad K, Stahlmann R. Drug interactions during therapy with three major groups of antimicrobial agents. Expert Opin Pharmacother 2006 Apr; 7(6): 639–51
Keating GM. Posaconazole. Drugs 2005; 65(11): 1553–67
Wu CY, Benet LZ. Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm Res 2005 Jan; 22(1): 11–23
Marty FM, Rubin RH. The prevention of infection post-transplant: the role of prophylaxis, preemptive and empiric therapy. Transpl Int 2006 Jan; 19(1): 2–11
Romero AJ, Pogamp PL, Nilsson LG, et al. Effect of voriconazole on the pharmacokinetics of cyclosporine in renal transplant patients. Clin Pharmacol Ther 2002 Apr; 71(4): 226–34
Tintillier M, Kirch L, Goffin E, et al. Interaction between voriconazole and tacrolimus in a kidney-transplanted patient. Nephrol Dial Transplant 2005 Mar; 20(3): 664–5
Mathis AS, Shah NK, Fiedman GS. Combined use of sirolimus and voriconazole in renal transplantation: a report of two cases. Transplant Proc 2004 Nov; 36(9): 2708–9
Sansone-Parsons A, Krishna G, Martinho M. Effect of oral posaconazole on the pharmacokinetics of cyclosporine and tacrolimus. Pharmacotherapy 2007 Jun; 27(6): 825–34
Dunn C, Croom KF. Everolimus: a review of its use in renal and cardiac transplantation. Drugs 2006; 66(4): 547–70
Certican® (everolimus) 0.5 mg oral tablets [summary of product characteristics]. Rueil-Malmaison, France: No-vartis France, 2004
Goodwin ML, Drew RH. Antifungal serum concentration monitoring: an update. J Antimicrob Chemother 2008 Jan; 61(1): 17–25
Purkins L, Wood N, Ghahramani P, et al. Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens. Antimicrob Agents Chemother 2002 Aug; 46(8): 2546–53
Trifilio S, Ortiz R, Pennick G, et al. Voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant 2005 Mar; 35(5): 509–13
Marty FM, Lowry CM, Cutler CS, et al. Voriconazole and sirolimus coadministration after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2006 May; 12(5): 552–9
Smith J, Safdar N, Knasinski V, et al. Voriconazole therapeutic drug monitoring. Antimicrob Agents Chemother 2006 Apr; 50(4): 1570–2
Imhof A, Schaer DJ, Schwarz U, et al. Neurological adverse events to voriconazole: evidence for therapeutic drug monitoring. Swiss Med Wkly 2006 Nov 11; 136: 739–42
Pascual A, Calandra T, Bolay S, et al. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 2008 Jan 15; 46(2): 201–11
Boussaud V, Daudet N, Lillo A, et al. Painful sensory neuropathy in lung transplanted patients under voriconazole. J Heart Lung Transplant 2008; 27(2): 229–32
Smith J, Andes D. Therapeutic drug monitoring of anti-fungals: pharmacokinetic and pharmacodynamic considerations. Ther Drug Monit 2008; 30(2): 167–72
Kovarik JM, Beyer D, Schmouder RL. Everolimus drug interactions: application of a classification system for clinical decision making. Biopharm Drug Dispos 2006 Dec; 27(9): 421–6
Christians U, Jacobsen W, Benet LZ, et al. Mechanisms of clinically relevant drug interactions associated with tacrolimus. Clin Pharmacokinet 2002; 41(11): 813–51
Noxafil® (posaconazole) 40mg/mL oral suspension [summary of product characteristics]. Brussels, Belgium: Schering-Plough Europe, 2006
Vfend® (voriconazole) 200 mg oral tablets [summary of product characteristics]. Paris, France: Pfizer Europe, 2002
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Billaud, E.M., Antoine, C., Berge, M. et al. Management of Metabolic Cytochrome P450 3A4 Drug-Drug Interaction between Everolimus and Azole Antifungals in a Renal Transplant Patient. Clin. Drug Investig. 29, 481–486 (2009). https://doi.org/10.2165/00044011-200929070-00006
Published:
Issue Date:
DOI: https://doi.org/10.2165/00044011-200929070-00006